Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics SVP Finance Amy Bachrodt reported option exercises and share sales. On February 2, 2026, she exercised stock options for 4,844 and 156 shares of common stock at an exercise price of $10.42 per share.
That same day she sold 200 shares at $44.15, 4,064 shares at a weighted average price of $46.0305, and 736 shares at a weighted average price of $46.6323. The sales were effected under a Rule 10b5-1 trading plan. After these transactions, she directly owned 12,965 common shares, along with vested and vesting stock options.
Maze Therapeutics, Inc. executive Atul Dandekar reported an option exercise and planned share sales. On January 29, 2026, he exercised a stock option for 7,500 shares of common stock at $10.42 per share, from a fully vested award. The same day, he sold 7,500 common shares in three trades: 1,200 shares at $43.1844, 3,500 shares at $44.0419, and 2,800 shares at $45.008, all under a pre-established Rule 10b5-1 trading plan. After these transactions, he reported owning 10,503 shares of common stock and 66,643 stock options, all held directly.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and a stock sale. On January 22, 2026, she exercised stock options to acquire 2,497 and 2,503 shares of common stock at an exercise price of $10.42 per share. On the same date, she sold 5,000 shares of common stock at a weighted average price of $45.5224 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly held 12,965 shares of Maze Therapeutics common stock and retained stock options covering 486 and 7,869 shares, subject to monthly vesting schedules.
MAZE insider Sekar Kathiresan has filed a notice to sell 29,772 shares of common stock under Rule 144. The planned sale, with an aggregate market value of $1,210,937.40, is to be executed through Morgan Stanley Smith Barney LLC on or about January 16, 2026 on the NASDAQ market. The filing notes that 48,119,444 shares of the issuer’s common stock were outstanding.
The 29,772 shares to be sold were acquired on January 16, 2026 via a stock option exercise from the issuer, paid for in cash. Over the prior three months, Kathiresan sold additional common shares, including 10,000 shares on December 4, 2025 for gross proceeds of $425,423.00 and 27,500 shares on November 21, 2025 for gross proceeds of $984,588.00.
Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, reported an option exercise and related share sale. On January 7, 2026, he exercised a stock option for 25,156 shares of common stock at an exercise price of $10.42 per share, converting a previously held derivative position into common stock.
On the same day, he sold the same 25,156 shares of common stock at a weighted average price of $40.2011 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025, leaving him with 0 directly held common shares and 312,407 stock options outstanding. The sale price reflects multiple transactions between $40.00 and $40.55 per share.
Maze Therapeutics director Catherine A. Sohn reported a series of stock option exercises and related common share sales. On January 6, 2026, she exercised 2,493 stock options at an exercise price of $10.42 per share and sold 2,493 common shares at a weighted average price of $38.616 per share, leaving no common shares directly owned.
On January 7, 2026, she exercised additional options for 20,744, 2,895, and 3,281 common shares at an exercise price of $10.42 per share and then sold 26,920 common shares at a weighted average price of $39.1079 per share, again ending with 0 common shares directly held. Following these transactions, she continues to hold stock options, including 3,211, 316, and 5,805 derivative securities with expiration dates between 2031 and 2034.
Maze Therapeutics insider plans a new stock sale. A Form 144 notice shows that Catherine Sohn intends to sell up to 26,920 shares of Maze Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,052,784.67. The shares are listed as being sold on NASDAQ, with an approximate sale date of January 7, 2026, and 48,119,444 common shares outstanding.
The filing states that the 26,920 shares were acquired on January 7, 2026 via a stock option exercise from the issuer, paid in cash. It also discloses that during the past three months, Catherine Sohn sold 2,493 Maze Therapeutics common shares on January 6, 2026 for gross proceeds of $96,269.69. By signing, the seller represents they are not aware of undisclosed material adverse information about the company.
A shareholder of MAZE has filed a Form 144 notice to sell 2,493 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ on or about 01/06/2026. The shares to be sold were acquired the same day via a stock option exercise for cash. The filing lists an aggregate market value of $96,269.69 for the planned sale, compared with 48,119,444 shares outstanding of the same class. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about MAZE’s current or prospective operations.
Maze Therapeutics, Inc. officer Harold Bernstein reported option exercises and share sales. On January 2, 2026, he exercised stock options to acquire 4,432 shares of common stock at $10.42 per share and sold 4,432 shares of common stock at a weighted average price of $40.4304 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. On January 5, 2026, he exercised options to acquire an additional 412 shares at $10.42 and sold 412 shares at $40.00 per share. Following these transactions, he continued to hold stock options, including 337,563 option shares directly owned, which vest over time according to a set schedule.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and share sales in company stock. On January 2, 2026, she exercised stock options for 204 and 4,796 shares of common stock at an exercise price of $10.42 per share. These options relate to grants that vest monthly and one award that was fully vested as of March 1, 2025.
On the same date, she sold 2,405 shares at a weighted average price of $38.6995 and 2,595 shares at a weighted average price of $39.5689, in multiple trades within stated price ranges. After these transactions, she directly held 12,965 shares of common stock and 2,377 and 2,983 stock options. All trades were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.